nerd
Senior Member
- Messages
- 863
My wife, for example, has equally sky-high EBV antibodies, but no chronic fatigue.
The correlation of antibodies doesn't make them an adequate biomarker with sufficient specificity for chronic diseases. It just means that chronic diseases are more likely. The HLA genome also plays a large role when it comes to susceptibility to pathogen-induced chronic diseases. If you have a high antibody count, you either got infected with a large inoculum, or you got reinfected regularly (if you have a lot of intimate/personal contact), or you had a long infection phase due to your immune system, vitamin deficiency or stress and the many other contributing factors.
Does this indicate a remnant condition, rather than something treatable?
Everything is treatable if you have full knowledge of the underlying pathology and the right technology available. But this might take a lot of time to figure out, and a lot of interested parties demanding their share. If this theory is true, it is more than just a remnant/latent infection, and an antiviral treatment might not be the first choice, just as it isn't the right choice for SLE and other EBV-associated diseases. The presumed problem lies within lymphocytes and/or the lymphoid system. This makes it difficult. Only a part of the whole lymphocyte population circulates in the blood. There are existing immunological treatments such as immune modulation, lymphocyte transfusion, lymphocyte filtration, the surgical removal of lymph nodes and the thymus, which could be applied as they are already being applied for MG. They often work for MG but you can't remove the whole lymph system, so it's no wonder pill. This is why an extensive immunological diagnosis of the lymphoid system of CFS/ME patients could clarify important questions in a study. Is the thymus always affected, as for MG?
For MG, you also have adequate symptomatic treatment via AChE inhibitors. Because the core pathology of the disease is known, though not much of the pathogenesis. With CFS/ME, we aren't even at this point. I think this is because CFS/ME is too complex to narrow it down to a specific antibody group or biomarker. It's not much different for rheumatoid diseases. But rheumatoid diseases have been researched extensively. With CFS/ME research, it's more like everyone skips from diagnosis to treatment and hopes to achieve significant results because they focus on a single aspect of the disease's pathology that is known. Maybe the EncodeME study can soon clarify some questions by narrowing down the susceptible genes and which genes correlate with disease severity. This allows for some important inferences.